Cameron Gray - Jun 14, 2022 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role
Director
Signature
/s/ Cameron Gray by Colin Sandercock attorney-in-fact
Stock symbol
CUE
Transactions as of
Jun 14, 2022
Transactions value $
$1
Form type
4
Date filed
6/16/2022, 04:01 PM
Previous filing
Jan 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CUE Common Stock Exercise of in-the-money or at-the-money derivative security $165K +61.1K +9.02% $2.70 739K Jun 14, 2022 Direct
transaction CUE Common Stock Tax liability -$165K -51.6K -6.98% $3.20 687K Jun 14, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CUE Warrants Exercise of in-the-money or at-the-money derivative security $0 -61.1K -100% $0.00* 0 Jun 14, 2022 Common Stock 61.1K $2.70 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On June 14, 2022, the reporting person exercised a warrant to purchase 61,111 shares of the Issuers common stock for $2.70 a share. The reporting person paid the exercise price on a cashless basis, resulting in the Issuer withholding of 51,562 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 9,549 shares.